基本介紹
- 中文名：盧璽峰
- 學位/學歷：博士
- 職業：教師
- 專業方向：脂代謝紊亂的機制研究
- 任職院校：深圳大學醫學部基礎醫學院
研究方向,學術成果,學術兼職,
研究方向
脂代謝紊亂的機制研究
能量代謝調控的機制研究
學術成果
科研項目
1.國家自然科學基金面上項目，受體阻斷脂肪肝發生的關鍵機制：調節肝臟-脂肪互動對話？81870605，57萬，2019/1-2022/12，在研，主持
2.國家自然科學基金面上項目，中性粒細胞來源的顆粒蛋白Proteinase 3 通過調節肝臟-腸道菌群軸介導非酒精性脂肪肝炎的研究，8157040915，58萬，2016/1-2019/12，在研，第一參與人
3.國家自然科學基金青年項目，腎素（原）受體在LDL受體功能調節中的關鍵作用：一個血脂調節的新機制，81500667，18萬，2016/1-2018/12，已結題，主持
4.深圳市基礎項目，腎素（原）受體調節體內LDLR 及血脂水平的研究，JCYJ20160307160819191，30萬，2016/7-2018/6，已結題，主持
5.深圳市基礎項目，糖代謝紊亂影響糖尿病腎病進展的機制研究，JCYJ20170817093928508，30萬，2018/3-2020/3，在研，主持
6.深圳市基礎項目，代謝性炎症與脂代謝紊亂性疾病的基礎研究，JCYJ20140509172719310，2015/1-2016/12；已結題，參與
7.深圳大學科研啟動項目，腎素（原）受體的新功能：調節脂蛋白代謝，2015/6-2017/5；已結題，主持
8.廣東省醫學科學技術研究基金面上項目，腎素(原)受體在糖尿病腎病的發生髮展中的作用，A2015051，1萬，2015/7-2017/6，已結題，主持
代表性成果
1. Ren L, Lu X, Danser A H J. Revisiting the Brain Renin-Angiotensin System-Focus on Novel Therapies [J]. Curr Hypertens Rep, 2019, 21(4): 28.
2. Fan M, Wen Y, Ye D, Jin Z, Zhao P, Chen D, Lu X, He Q. Acid-Responsive H2 -Releasing 2D MgB2 Nanosheet for Therapeutic Synergy and Side Effect Attenuation of Gastric Cancer Chemotherapy [J]. Adv Healthc Mater, 2019, 8(13): e1900157.
3. Zhao P, Jin Z, Chen Q, Yang T, Chen D, Meng J, Lu X, Gu Z, He Q. Local generation of hydrogen for enhanced photothermal therapy. Nature Communications, 2018, 9(1): 4241.
4.Liu, J., Liu, Y., Yan, Y., Yang, J., Lu, X., Cheng, Y. Commiphoratones A and B, Two Sesquiterpene Dimers from Resina Commiphora. Organic Letters. 20 (8). 2018.
5.Song, Y., Liu, Y., Yan, Y., Lu, X., Cheng, Y. Phenolic Compounds from Belamcanda chinesis Seeds. Molecules. 2018.3.5.
6.Ren, L., Sun Y., Ruan, X., Lu, X. (Pro)renin Receptor Inhibition Reprograms Hepatic Lipid Metabolism and Protects Mice from Diet-induced Obesity and Hepatsteatosis. Circ Res. 2018.3.2,122(5):730-741.
7. Hu, X., Qin, Fu., Lu, X., Cheng, Y. Three New Polyynes from Codonopsis pilosula and Their Activities on Lipid Metabolism. Molecules. 2018. 23(4).
8.Yang, X., Okamura, D., Lu, X., Chen, Y., Moorhead, J., Varghese, Z., Ruan, X. CD36 in Chronic Kidney Disease: Novel Insights and Therapeutic Opportunities. Nature Reviews Nephrology. 2017.12,13(12):769：781.
9.Sun, Y., Danser, AHJ., Lu, X. (Pro) renin Receptor as a Therapeutic Target for the treatment of Cardiovascular Diseases? Pharmacological Research. 2017.7.125：48-56.
10.Zhu, X., Yan, Y., Ai, C., Jiang, S., Xu, S., Niu, M., Wang, X., Zhong, G., Lu, X., Xue, Y., Tian, S., Li, G., Tang, S., Jiang., Y. Jarid2 is essential for the maintenance of tumor initiating cells in bladder cancer. Oncotarget. 2017. 11; 8(15): 24483–24490.
11.Chen, D., Zhu, X., Yan, Y., Ai, C., Lu, X., Xu, S., Jiang, S., Zhong, G., Chen, D., Jiang., Y. Long Non-coding RNA HoxA-AS3 interacts with EZH2 to Regulate Lineage Commitment of Mesenchymal Stem Cells. Oncotarget. 2016. 7(39):63561-63570
12.Daryadel, A., Bourgeois, S., Figueiredo, MF., Gomes Moreira, A., Kampik, NB., Oberli, L., Mohebbi, N.,
Lu, X., Meima, ME., Danser, AH., and Wagner, CA., Colocalization of the (Pro)renin Receptor/Atp6ap2 with H+-ATPases in Mouse Kidney but Prorenin Does Not Acutely Regulate Intercalated Cell H+-ATPase Activity. PLoS One., 11(1):e0147831.
13.Lu, X., Meima, M., et al., Identification of the (Pro)renin receptor as a Novel Regulator of Lipoprotein Metabolism. Circ Res. 2016. 118(2):222-9.
14.Lu, X., Krop, M., et al., Renin inhibitor VTP-27999 differs from aliskiren: focus on their intracellular accumulation and the (pro)renin receptor. J Hypertens, 2014. 32(6):1255-63.
15.Lu, X., L.C. Roksnoer, and A.H. Danser, The intrarenal renin-angiotensin system: does it exist? Implications from a recent study in renal angiotensin-converting enzyme knockout mice. Nephrol Dial Transplant, 2013. 28(12): p. 2977-82.
16.Persson, F*., Lu X* et al., Urinary renin and angiotensinogen in type 2 diabetes: added value beyond urinary albumin? J Hypertens, 2013. 31(8): p. 1646-52. *: Joint first authors.
17.Lu, X., et al., (Pro)renin receptor is required for prorenin-dependent and -independent regulation of
vacuolar H(+)-ATPase activity in MDCK.C11 collecting duct cells. Am J Physiol Renal Physiol, 2013. 305(3): p. F417-25.
18.Krop, M., Lu X, et al., New renin inhibitor VTP-27999 alters renin immunoreactivity and does not unfold prorenin. Hypertension, 2013. 61(5): p. 1075-82.
19.Krop, M., Lu X, et al., The (pro)renin receptor. A decade of research: what have we learned?
Pflugers Arch, 2013. 465(1): p. 87-97.
20.Batenburg, W.W., Lu X, et al., Renin- and prorenin-induced effects in rat vascular smooth muscle cells overexpressing the human (pro)renin receptor: does (pro)renin-(pro)renin receptor interaction actually occur? Hypertension, 2011. 58(6): p. 1111-9.
21.Lu, X., A.H. Danser, and M.E. Meima, HRP and prorenin: focus on the (pro)renin receptor and vacuolar H+-ATPase. Front Biosci (Schol Ed), 2011. 3: p. 1205-15.
近年來在國際知名期刊Circulation Research、Organic Letters、Nature Review Nephrology、Pharmacological Research、Journal of Hypertension、AJP-Renal Physiology等雜誌發表論文14篇；申請國家發明專利1項。主持國家自然科學基金青年基金1項，國家自然科學基金面上項目1項，省市級項目3項；深圳市海外高層次人才計畫C類；獲深圳大學“荔園優青”項目支持。
學術兼職
目前擔任Journal of Renin-Angiotensin-System以及American Journal of Hypertension雜誌的審稿人。
